期刊文献+

组织因子和组织因子途径抑制物与心肌无复流 被引量:4

下载PDF
导出
摘要 组织因子(TF)是凝血途径的启动因子,与动脉粥样硬化的病理生理过程及临床并发症密切相关。凝血和炎症共同作用导致动脉粥样硬化,二者也是心肌无复流的发生发展基础,TF将凝血和炎症紧密联系,使二者相互作用。近些年发现心肌缺血再灌注损伤的动物模型中,缺血心肌TF表达增高,应用抑制TF的单抗可使心肌梗死面积减少,实验动物输注TF可促进心肌无复流的发生。急性冠状动脉无复流的患者TF水平也升高。TF可作为心肌无复流的预测指标。组织因子途径抑制物(TFPI)是TF的生理抑制剂,动物实验表明TFPI有抗血栓、抗炎症、抗增殖作用,输注TFPI可减轻心肌无复流的程度,为治疗心肌无复流开辟了新领域。
作者 黎娜 李宪伦
出处 《中国循环杂志》 CSCD 北大核心 2011年第4期317-319,共3页 Chinese Circulation Journal
  • 相关文献

参考文献15

  • 1Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon:from the experimental laboratory to the cardiac catheterization laboratory. Cath- eter cardiovasc interv,2008, 72 (7) :950-957.
  • 2Chong A J, Pohlman TH, Hampton CR, et al. Tissue factor and thrombin mediate myocardial ischemia-reperfusion injury. Ann Thorac Surg,2003,75 (2) : S649-655.
  • 3Bonderman D, Teml A, Jakowitsch J, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerot- ic plaque. Blood, 2002,99 (8) :2794-2800.
  • 4徐萍,齐晓云,李春华,张继红,刘冬梅,刘洁,王万粮.急性心肌梗死患者直接介入治疗后无再流与血浆组织因子及其途径抑制物的关系[J].中华心血管病杂志,2008,36(11):1013-1015. 被引量:6
  • 5Migdalski A, Kotschy M, Jawien A. Tissue factor, tissue factor path- way inhibitor and vascular endothelial growth factor-A in carotid ather- osclerotic plaques. Eur J Vasc Endovasc Surg,2005,30( 1 ) :41-47.
  • 6Park CT, Creasey AA, Wright SD. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and inter- fering with transfer to CD14. Blood, 1997,89(12) :4268-4274.
  • 7Westrick RJ, Bodary PF, Xu Z, et al. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation, 2001,103 ( 25 ) :3044-3046.
  • 8Maroney SA, Cooley BC, Ferrel JP, et al. Murine hematopoietic cell tissue factor pathway inhibitor limits thrombus growth. Arterioscler Thromb Vasc Biol, 2011,31 (4) : 821-826.
  • 9Nakamura Y, Nakamura K, Ohta K, et al. Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor path- way inhibitor after balloon angioplasty. Basic Res Cardiol, 2002,97 (3) :198-205.
  • 10Kopp CW, Holzenbein T, Steiner S, et al. Inhibition of restenosis by tissue factor pathway inhibitor: in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activ- ity. Blood, 2004,103 ( 5 ) : 1653-1661.

二级参考文献24

  • 1Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infalction after percutaneous coronary intervention. Am Heart J, 2003, 145 : 42- 46.
  • 2Brosh D, Assali AR, Mager A, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol, 2007,99 : 442- 445.
  • 3Bonderman D, Teml A, Jakowitsch J, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaques. J Blood, 2002,99:2794-2800.
  • 4Migdalski A, Kotschy M, Jawien A. Tissue factor, tissue factor pathway inhibitor and vascular endothelial growth factor-A in carotid atherosclerotic plaques. Eur J Vasc Endovasc Surg, 2005, 30:41-47.
  • 5Iwaknra K, ho H, lkushima M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coil Cardiol,2003,41:1-7.
  • 6Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med, 1995,46 : 103-112.
  • 7Golino P, Ragni M, Cimmino G, et al. Role of tissue factor pathway inhibitor in the regulation of tissue factor dependent blood coagulation. Cardiovasc Drug Rev,2002 ,20 :67-80.
  • 8Brosh D, Assali AR, Mager A, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol, 2007,99:442- 445.
  • 9Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv, 2008, 72:950-957.
  • 10Golino P,Ragni M, Cirillo P, et al. Recombinant human, active site-blocked factor VII a reduces infarct size and no-reflow phenomenon in rabbits. Am J Physiol Heart Circ Physiol, 2000, 278 : 1507-1516.

共引文献9

同被引文献43

  • 1张高峰,许澎,伍旭升,周亚刚,乔祺,俞利群,施旭荣,徐岭,朱艳.冠状动脉内药物支架与非药物支架置入对组织因子和组织因子途径抑制物的影响[J].中国循环杂志,2006,21(5):330-332. 被引量:9
  • 2Ardissino D,Merlini PA,Arlens R,et al.Tissue factor in human coronary atheresclerotic plaques[J].Clin Chim Acta,2009,291:235-240.
  • 3Steppich B,Mattisek C,Sobczyk D,et al.Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction[J].Thromb Haemost,2008,93:35-39.
  • 4Osterud B. Tissue factor/TFPI and blood cells[J]. Thrombosis Research,2012,129(3):274-278.
  • 5Girard TJ, Tuley E, Broze GJ. TFPIp is the GPI-anchored TFPI iso-form on human endothelial cells and placental microsomes[J]. Blood,2012,119(5):1256-1262.
  • 6Rezkalla SH,Kloner RA.Coronary no-reflow phenomenon:from theexperimental laboratory to the cardiac catheterization laboratory.Catheter Cardiovasc Interv,2008,72:950-957.
  • 7Tanriverdi H,Evrengul H,Kilic ID,et al.Aortic pressures,stiffness and left ventricular function in coronary slow flow phenomenon.Cardiology,2010,116:261-267.
  • 8Morishima I,Sone T,Okumura K,et al.Angiographic no-reflowphenomenon as a predictor of adverse long-term outcome in patientstreated with percutaneous transluminal coronary angioplasty for firstacute myocardial infarntion.J Am Coll Cardiol,2000,36:1202-1209.
  • 9Resnic FS,Wainstein M,Lee MK,et al.No-reflow is an independentpredictor of death and myocardial infarction after percutaneouscoronary intervention.Am Heart J,2003,145:42-46.
  • 10Pedroza M,Schneider DJ,Karmouty-Quintana H,et al.Interleukin-6 contributes to inflammation and remodeling in a modelof adenosine mediated lung injury.PLoS One,2011,6:e22667.

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部